Discover how PLX-3618, a molecular degrader, is revolutionizing prostate cancer treatment by eliminating the BRD4 protein rather than just inhibiting it.
Explore how BRD4-targeting PROTACs are transforming multiple myeloma treatment through targeted protein degradation technology.